Pappas Capital, one of the top life science investment firms in the southeast, has made changes in its management team, promoting two executives to different roles as it observes 25 years in business.
Read MoreA.M. Pappas Life Science Ventures has closed on a new $85.7 million fund.
Read More
Kenneth Moch, a former CEO of Chimerix, has retracted allegations made against Pappas Ventures and also agreed to pay a settlement in a case dating back to October 2014.
Read MoreThomas Mathers, former CEO of CoLucid Pharmaceuticals, is joining Pappas Capital as a venture partner, and his primary task is to focus on the formation of a new biopharmaceutical firm.
Read More
Pappas Capital is adding a new partner, someone who is already familiar with the Triangle-based firm.
Read More
